The Biotech Startups Podcast - 🧬Chris Moxham - Transcripta Bio - Part 2 | From Eli Lilly Recruit to NYC Lab Builder | Leading High-Stakes Drug Discovery | Pioneering Quantitative Biology | "Making the Trains Run on Time"

🧬Chris Moxham - Transcripta Bio - Part 2 | From Eli Lilly Recruit to NYC Lab Builder | Leading High-Stakes Drug Discovery | Pioneering Quantitative Biology | "Making the Trains Run on Time"

11/14/24 • 29 min

The Biotech Startups Podcast is brought to you by Excedr. Excedr provides life science startups with equipment leases on founder-friendly terms to accelerate R&D and commercialization.Know anyone that needs lab equipment? Join Excedr’s referral program: Give Your Friends $1,000, and Earn $1,000 for Each Qualified Referral 💸.Get your unique referral link by going to: refer.excedr.com/ZTHETY.Part 2 of 4: Jon Chee hosts Chris Moxham, the Co-Founder, CEO, and CSO of Transcripta Bio, a pioneering biotech company charting a faster path in drug discovery to create better lives for people around the world.Chris earned his PhD in Molecular and Cellular Pharmacology at Stony Brook University and is a seasoned veteran with over 25 years of drug discovery experience, having spent two decades at Eli Lilly where he was instrumental in advancing over 10 molecules into clinical trials across multiple therapeutic areas and both small and large molecule modalities. Chris has a wealth of knowledge, and his commitment to both scientific advancement and team growth makes his insights invaluable for aspiring leaders in biotech.Join us this week to hear about:

How he got recruited to Eli Lilly through persistent outreach by VP Jose Caro, who recognized Chris's potential
How Chris advanced rapidly from obesity research to heading lead generation biology at Lilly Indianapolis
His experience successfully leading a complex $20M lab buildout in NYC after Lilly's ImClone acquisition
Transitioning to biotech as CSO at Fulcrum Therapeutics, where he gained valuable experience in investor relations and helped raise $200M in public markets
What it means to serve as CEO developing an innovative "drug machine" platform that combines machine learning with wet lab approaches

Please enjoy Jon’s conversation with Chris Moxham.Subscribe to the podcast: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994Find Our Guest, Chris Moxham, at these links: https://www.linkedin.com/in/christopher-moxham-b8867011/ https://www.transcriptabio.com/ Find Our Host, Jon Chee, at these links: https://www.linkedin.com/in/jonchee https://www.excedr.comExcedr Socials & WebsiteLinkedIn: https://www.linkedin.com/company/excedr/ Youtube: https://www.youtube.com/@excedr Instagram: https://www.instagram.com/excedr_inc Twitter: https://twitter.com/ExcedrInc Facebook: https://www.facebook.com/excedr TikTok: https://www.tiktok.com/@excedr Podcast Website: https://www.thebiotechstartupspodcast.com/ Enriched Notes:

Topics Mentioned:Eli Lilly https://en.wikipedia.org/wiki/Eli_Lilly_and_Company ImClone https://en.wikipedia.org/wiki/ImClone_Systems Merck https://en.wikipedia.org/wiki/Merck_%26_Co. Fulcrum Therapeutics https://www.fulcrumtx.com/Marketing & Sales Tools for Biotechs: https://www.excedr.com/blog/marketing-sales-strategies-for-biotechsBiotech Partnerships: How Partnering with Big Pharma Can Support R&D: https://www.excedr.com/blog/how-biotech-partnerships-support-researchHow to Bootstrap a Biotech Tools Startup: https://www.excedr.com/resources/how-to-bootstrap-biotech-startupPeople Mentioned:Jose Caro https://www.linkedin.com/in/josefcaro/ Timestamps:00:49 Intro02:31 "The Power of Persistence in Recruiting" - How Jose Caro's personal outreach convinced Chris to join Eli Lilly05:31 Early days at Lilly: Transitioning from obesity research to high-throughput screening platforms08:18 Leadership evolution: Key lessons in scaling from small teams to managing 45+ scientists12:16 Cu...

How he got recruited to Eli Lilly through persistent outreach by VP Jose Caro, who recognized Chris's potential
How Chris advanced rapidly from obesity research to heading lead generation biology at Lilly Indianapolis
His experience successfully leading a complex $20M lab buildout in NYC after Lilly's ImClone acquisition
Transitioning to biotech as CSO at Fulcrum Therapeutics, where he gained valuable experience in investor relations and helped raise $200M in public markets
What it means to serve as CEO developing an innovative "drug machine" platform that combines machine learning with wet lab approaches

Previous Episode

undefined - 🧬Chris Moxham - Transcripta Bio - Part 1 | From Long Island to Biotech Pioneer | Cornell's Pivotal Role in Research Passion | Strategic Leap to Pharma Industry | Cultivating Effective Leadership in Science

🧬Chris Moxham - Transcripta Bio - Part 1 | From Long Island to Biotech Pioneer | Cornell's Pivotal Role in Research Passion | Strategic Leap to Pharma Industry | Cultivating Effective Leadership in Science

The Biotech Startups Podcast is brought to you by Excedr. Excedr provides life science startups with equipment leases on founder-friendly terms to accelerate R&D and commercialization.Know anyone that needs lab equipment? Join Excedr’s referral program: Give Your Friends $1,000, and Earn $1,000 for Each Qualified Referral 💸.Get your unique referral link by going to: refer.excedr.com/ZTHETY.Part 1 of 4: Jon Chee hosts Chris Moxham, the Co-Founder, CEO, and CSO of Transcripta Bio, a pioneering biotech company charting a faster path in drug discovery to create better lives for people around the world.Chris earned his PhD in Molecular and Cellular Pharmacology at Stony Brook University and is a seasoned veteran with over 25 years of drug discovery experience, having spent two decades at Eli Lilly where he was instrumental in advancing over 10 molecules into clinical trials across multiple therapeutic areas and both small and large molecule modalities. Chris has a wealth of knowledge, and his commitment to both scientific advancement and team growth makes his insights invaluable for aspiring leaders in biotech.Join us this week to hear about:

Chris’ childhood growing up on Long Island and his experience with early heart surgery at 12 years old
How those early experiences shaped his passion for science and medicine
His pivotal experiences at Cornell University, where a summer fellowship studying insulin signaling sparked his transition from pre-med to research
His groundbreaking PhD research at SUNY Stony Brook developing transgenic mice, leading to publications in Science and Nature
The strategic decision to pursue pharmaceutical research over academia, leveraging key connections to launch his industry career at Wyeth
His leadership philosophy’s emphasis on respect, teamwork, and balancing immediate results with long-term vision

Please enjoy Jon’s conversation with Chris Moxham.Subscribe to the podcast: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994
Find Our Guest, Chris Moxham, at these links: https://www.linkedin.com/in/christopher-moxham-b8867011/ https://www.transcriptabio.com/ Find Our Host, Jon Chee, at these links: https://www.linkedin.com/in/jonchee https://www.excedr.comExcedr Socials & WebsiteLinkedIn: https://www.linkedin.com/company/excedr/ Youtube: https://www.youtube.com/@excedr Instagram: https://www.instagram.com/excedr_inc Twitter: https://twitter.com/ExcedrInc Facebook: https://www.facebook.com/excedr TikTok: https://www.tiktok.com/@excedr Podcast Website: https://www.thebiotechstartupspodcast.com/ Enriched Notes:

Topics Mentioned:Cornell https://www.cornell.edu/ SUNY Stony Brook https://www.stonybrook.edu/ Malbon Laboratory https://www.pharm.stonybrook.edu/faculty_research/directory/m/malbon-craig/laboratory Wyeth https://en.wikipedia.org/wiki/WyethMarketing & Sales Tools for Biotechs: https://www.excedr.com/blog/marketing-sales-strategies-for-biotechsBiotech Partnerships: How Partnering with Big Pharma Can Support R&D: https://www.excedr.com/blog/how-biotech-partnerships-support-researchHow to Bootstrap a Biotech Tools Startup: https://www.excedr.com/resources/how-to-bootstrap-biotech-startupTimestamps:00:49 Intro03:18 Chris's upbringing as the youngest of 7 children on Long Island06:07 The influence of Chris's parents on his leadership style08:20 Family dynamics and expectations growing up in a large household11:06 Choosing Cornell University and the path to pre-med14:30 Securing research opportunities and working with scientific luminaries as...

Next Episode

undefined - 🧬Chris Moxham - Transcripta Bio - Part 3 | Embracing the Startup Challenge | Mastering Science-to-Business Communication | Building a Scalable Discovery Engine | Leveraging AI & Genetics in Drug Development

🧬Chris Moxham - Transcripta Bio - Part 3 | Embracing the Startup Challenge | Mastering Science-to-Business Communication | Building a Scalable Discovery Engine | Leveraging AI & Genetics in Drug Development

The Biotech Startups Podcast, brought to you by Excedr—empowering life science startups with founder-friendly equipment leasing to fast-track R&D and drive commercialization success.Know someone in need of lab equipment? Join Excedr’s referral program: Give your friends $1,000 and earn $1,000 for every qualified referral! 💸Get your unique referral link here: refer.excedr.com/ZTHETY.
Part 3 of 4: Jon Chee hosts Chris Moxham, Co-Founder, CEO, and CSO of Transcripta Bio—a pioneering biotech company accelerating drug discovery to improve lives worldwide.With a PhD in Molecular and Cellular Pharmacology from Stony Brook University and over 25 years in drug discovery, Chris brings a wealth of experience. During his two-decade tenure at Eli Lilly, he advanced over 10 molecules into clinical trials across multiple therapeutic areas, spanning both small and large molecule modalities.Chris’s deep expertise and dedication to scientific innovation and team development offer invaluable insights for aspiring biotech leaders.Join us this week to hear about:

Chris’ transition from Eli Lilly to the startup world, embracing the excitement and uncertainty of a smaller company.
Navigating investor relations and honing the skill of translating science into business language.
Developing Transcripta Bio’s discovery engine, a scalable approach to drug discovery.
Leveraging AI, genetics, and high-throughput data to reduce failure points in drug development.